| Literature DB >> 34146515 |
Yi Shiau Ng1, Laurence A Bindoff2, Gráinne S Gorman1, Thomas Klopstock3, Cornelia Kornblum4, Michelangelo Mancuso5, Robert McFarland6, Carolyn M Sue7, Anu Suomalainen8, Robert W Taylor6, David R Thorburn9, Doug M Turnbull10.
Abstract
Mitochondrial diseases are some of the most common inherited neurometabolic disorders, and major progress has been made in our understanding, diagnosis, and treatment of these conditions in the past 5 years. Development of national mitochondrial disease cohorts and international collaborations has changed our knowledge of the spectrum of clinical phenotypes and natural history of mitochondrial diseases. Advances in high-throughput sequencing technologies have altered the diagnostic algorithm for mitochondrial diseases by increasingly using a genetics-first approach, with more than 350 disease-causing genes identified to date. While the current management strategy for mitochondrial disease focuses on surveillance for multisystem involvement and effective symptomatic treatment, new endeavours are underway to find better treatments, including repurposing current drugs, use of novel small molecules, and gene therapies. Developments made in reproductive technology offer women the opportunity to prevent transmission of DNA-related mitochondrial disease to their children.Entities:
Year: 2021 PMID: 34146515 DOI: 10.1016/S1474-4422(21)00098-3
Source DB: PubMed Journal: Lancet Neurol ISSN: 1474-4422 Impact factor: 44.182